Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Geographic Atrophy
Clinical trial register · United States · industry-sponsored

Geographic Atrophy Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9107 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 02 Oct 2026, 03:16 UTC
9107
Studies in scope
industry-sponsored, all four open statuses
4948
Recruiting now
open to new participants
2191
Lead sponsors
across recruiting studies
Top states
California 15 Florida 12 Arizona 10 Illinois 9 Maryland 8
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Geographic Atrophy trials in the USA

20 of 9107 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT07807969Geographic Atrophy
Annexon, Inc.
Phase 3
605
Florida, Maryland, Massachusetts, North Carolina, Oregon
2026-09-30
Recruiting
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07029945Geographic Atrophy
Biojiva LLC
Phase 1/2
152
Arizona, Mississippi, Nevada, Ohio, Texas, Utah, Washington
2026-09-29
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2026-09-11
Recruiting
Phase 1 Study of C.001 in Retinal Degeneration
NCT07594236Geographic Atrophy, Stargardt Disease, RPE-mediated Maculopathy, Age Related Macular Degeneration
Cellio Therapeutics Inc
Phase 1
15
California
2026-04-07
Recruiting
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234Geographic Atrophy
Sanofi
Phase 1/2
104
Arizona, California, Florida, Georgia, Illinois, Maryland, Nevada, North Carolina
2025-10-09
Recruiting
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07160179Geographic Atrophy, Age-Related Macular Degeneration
AbbVie
Phase 1/2
66
Indiana, Nevada, Texas
2025-08-13
Recruiting
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
NCT06557460Dry Age-related Macular Degeneration, Geographic Atrophy
Regenerative Patch Technologies, LLC
Phase 2
24
California, Illinois, Texas
2025-08-01
Active, closed
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06769048Geographic Atrophy
Boehringer Ingelheim
Phase 2
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-01-31
Recruiting
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
NCT06805474Macular Degeneration, Geographic Atrophy, Stargardt Disease
Nanoscope Therapeutics Inc.
Observational
30
Texas
2025-01-28
Active, closed
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773Geographic Atrophy, Macular Degeneration
Astellas Pharma Global Development, Inc.
Observational
489
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2025-01-22
Active, closed
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06722157Macular Degeneration, Age-related, Geographic Atrophy
Boehringer Ingelheim
Phase 2
202
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-01-06
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148Geographic Atrophy, Macular Degeneration
Janssen Research & Development, LLC
Phase 2/3
274
Arizona, California, Florida, Georgia, Illinois, Indiana, Maine, Maryland
2024-09-19
Active, closed
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816Geographic Atrophy
Annexon, Inc.
Phase 3
659
Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois, Iowa
2024-07-30
Active, closed
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT06161584Geographic Atrophy
Apellis Pharmaceuticals, Inc.
Observational
300
California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, New Jersey
2023-09-28
Active, closed
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593Geographic Atrophy
Belite Bio, Inc
Phase 3
429
Arizona, California, Florida, Maryland, Minnesota, New York, North Carolina, Oregon
2023-07-27
Active, closed
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
NCT06087458Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
Perceive Biotherapeutics, Inc.
Phase 1/2
60
Arizona, California, Massachusetts, Missouri, New Jersey, Oregon, South Dakota, Texas
2023-06-21
Active, closed
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
NCT06018558Geographic Atrophy
Ocugen
Phase 1/2
60
Arizona, Florida, Indiana, Mississippi, Missouri, New Jersey, North Carolina, Pennsylvania
2023-02-23
Active, closed
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
NCT05797896Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration
Complement Therapeutics
Observational
250
California, Indiana, Maryland, Nevada, Oregon, Pennsylvania, Texas
2023-02-07
Recruiting
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
NCT05438732Age-Related Macular Degeneration, Geographic Atrophy
VisionCare, Inc.
Not applicable
125
California, Florida, Massachusetts, Michigan, Nebraska, New Jersey, North Carolina, Ohio
2022-06-16
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/geographic-atrophy

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,107 studies in total at the last sync on 02 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies listing the condition Geographic Atrophy.

How many Geographic Atrophy trials are recruiting in the US?

10 of the 20 studies on this page are recruiting new participants as of the 02 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Geographic Atrophy), 20 studies
PhaseStudiesRecruitingShare
Phase 1/25325%
Phase 25325%
Observational4120%
Phase 33015%
Not applicable115%
Phase 1115%
Phase 2/3115%

Most active sponsors

Lead sponsors with the most studies (Geographic Atrophy)
Lead sponsorStudiesRecruiting
Annexon, Inc.20
Boehringer Ingelheim20
AbbVie11
Apellis Pharmaceuticals, Inc.10
Astellas Pharma Global Development, Inc.10
Belite Bio, Inc10
Biojiva LLC11
Cellio Therapeutics Inc11
Complement Therapeutics10
Genentech, Inc.11

Top states

Top states (Geographic Atrophy), by number of studies with a site there
StateStudies
California15
Florida12
Arizona10
Illinois9
Maryland8
Georgia7
Colorado6
North Carolina6
Texas6
Nevada5
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.